PositiveID and DirectView Security Systems Enter Into Co-Marketing Agreement to Jointly Market Products to Homeland Security and First Responders

Companies to cross market PositiveID's biological detection and diagnostic solutions with DirectView's video surveillance and body worn camera technologies

Jun 10, 2015, 08:00 ET from PositiveID Corporation

DELRAY BEACH, Florida, June 10, 2015 /PRNewswire/ -- PositiveID Corporation ("PositiveID" or "Company") (OTCQB: PSID), a developer of biological detection and diagnostics solutions, announced today that it has entered a co-marketing agreement with DirectView Security Systems, Inc. ("DirectView") (OTC: DIRV), a provider of video surveillance systems including body worn cameras, to jointly market  the companies' products to homeland security and first responders.

PositiveID develops molecular diagnostic systems, including Firefly Dx, which is designed to provide real-time, accurate diagnostic results in a handheld device, thereby leading to treatment scenarios at the point of need that are not possible with existing systems, which require lab-based equipment and can take hours or even days to provide results. Firefly's applications for first responders include point-of-need, lab-quality detection of pathogenic organisms and detection of biological agents associated with weapons of mass destruction. 

DirectView provides, among other products and services, body worn cameras, video storage servers, digital video recorders, and network video recorders, to address the needs of first responders.

"We are excited to enter into this co-marketing agreement with DirectView to include video surveillance solutions and body worn cameras to our line of first responder products," stated William J. Caragol, Chairman and CEO of PositiveID. "Through collaborating with companies like DirectView we accomplish two important goals: adding synergistic products and leveraging the sales channels of both companies to maximize our efforts and achieve better results."

About PositiveID Corporation

PositiveID Corporation is an emerging growth company and developer of biological detection systems for America's homeland defense industry as well as rapid biological testing. PositiveID is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats and analyze biological samples. For more information on PositiveID, please visit http://www.psidcorp.com, or connect with PositiveID on Twitter, Facebook or LinkedIn.

About DirectView Holdings, Inc.

DirectView Holdings, Inc., together with its subsidiaries, provides video surveillance solutions and teleconferencing products and services to businesses and organizations. The company operates in two divisions, Security (Video Surveillance) and Video Conferencing. The Security division offers technologies in surveillance systems providing onsite and remote video and audio surveillance, digital video recording, and services. It also sells and installs surveillance systems; and sells maintenance agreements. The company sells its products and services in the United States and internationally through direct sales force, referrals, and its Websites. The Video Conferencing division offers teleconferencing products and services that enable clients to conduct remote meetings by linking participants in geographically dispersed locations. It is involved in the sale of conferencing services based upon usage, the sale and installation of video equipment, and the sale of maintenance agreements. This division primarily provides conferencing products and services to numerous organizations ranging from law firms, banks, high tech companies and government organizations. For more information visit our website at www.DirectView.com and connect with us on Twitter, LinkedIn, Facebook, and Google+.

Statements about PositiveID's future expectations, including the likelihood that Firefly Dx is designed to provide real-time, accurate diagnostic results in a handheld device, thereby leading to treatment scenarios at the point of need that are not possible with existing systems, which require lab-based equipment and can take hours or even days to provide results; the likelihood that through collaborating with companies like DirectView the Company accomplishes two important goals: adding synergistic products and leveraging the sales channels of both companies to maximize our efforts and achieve better results; constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include, without limitation, the Company's ability to target the bio-threat detection and rapid medical testing sectors; the Company's ability to complete the development of its Firefly Dx system; as well as other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 30, 2015, and 10-Qs filed on May 15, 2015, November 17, 2014, and August 14, 2014, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Contact:
PositiveID Corporation
Allison Tomek
+1-561-805-8044
atomek@positiveidcorp.com

SOURCE PositiveID Corporation



RELATED LINKS

http://www.psidcorp.com